Miguel Islas-Ohlmayer, M.D.
Hematology, Blood and Marrow Transplantation
Patient Reviews Request Appointment
Miguel Islas-Ohlmayer, MD is a hematologist, blood and marrow transplant specialist, and cellular therapy specialist. His specialty is hematology, and he has a particular interest in blood cancers and blood and marrow stem cell transplantation. He is actively involved in cancer research and serves as principal investigator for lymphoma clinical trials at OHC.
Dr. Islas-Ohlmayer has a passion for helping cancer patients, especially those who are facing difficult situations. “One of the most challenging diagnoses is leukemia, and I want to help these patients and their families make it through a very tough period in their lives. We have a great team at OHC who work together to make sure patients feel supported during their cancer fight.”
In his free time, Dr. Islas-Ohlmayer enjoys spending time with his two beautiful daughters.
Education & Training
Medical School: Universidad de Monterrey School of Medicine, Monterrey, Mexico
Residency: Valley Baptist Medical Center/University of Texas Health Center, Houston, TX
Fellowship: University of Texas Southwestern Medical Center
Fellowship: University of Texas Health Science Center/Texas Transplant Institute
American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Hematology
Dr. Islas takes the time to have a conversation about what issues are going on. Never once felt like I didn't have his attention. He was able to describe things in terms I understood. – S., May 2022
I am very confident and thankful to Dr. Islas-Ohlmayer! His staff is courteous and he is a very wonderful physician! – Anonymous, May 2022
From the moment I walked into OHC, I was extremely pleased. Starting with the front desk staff, the MA that took me back after getting my blood, the MD, and even checking out. If all offices worked well like this, it would truly be a blessing! – S.H., May 2022
My new oncologist, Dr. Islas, took the time to explain my previous lab findings and what we would be looking for in the future. As a retired physician, I was very impressed with him. – J.S., April 2022